Drug · CHEMBL44657

ETOPOSIDE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. ETOPOSIDE. Drugs and targets, record CHEMBL44657. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL44657

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: ETOPOSIDE; ChEMBL
ChEMBL ID: CHEMBL44657; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Toposar, Vepesid; ChEMBL
Other names: Etoposide resolution mixture, Etoposido, Etoposidum, NSC-141540, Sintopozid, VP-16-213; ChEMBL
DrugBank: DB00773; DrugBank
InChIKey: VJJPUSNTGOMMGY-MRVIYFEKSA-N; ChEMBL
Open Targets' highest stage: Approval, for 5 of its 218 diseases, from ATC, DailyMed and TTD; Open Targets

Targets2

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
TOP2A	DNA topoisomerase II	DNA topoisomerase II inhibitor	INHIBITOR	https://conductscience.org/library/genes/7153
TOP2B	DNA topoisomerase II	DNA topoisomerase II inhibitor	INHIBITOR	https://conductscience.org/library/genes/7155

Source ChEMBL

Diseases218

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
small cell lung carcinoma	Approval	DailyMed	255	253	https://conductscience.org/library/drugs?q=MONDO_0008433
non-Hodgkin lymphoma	Phase 3	ClinicalTrials.gov	143	143	https://conductscience.org/library/drugs?q=MONDO_0018908
acute myeloid leukemia	Phase 3	ClinicalTrials.gov	122	122	https://conductscience.org/library/drugs?q=MONDO_0018874
acute lymphoblastic leukemia	Phase 3	ClinicalTrials.gov	99	99	https://conductscience.org/library/drugs?q=MONDO_0004967
Hodgkins lymphoma	Phase 3	ClinicalTrials.gov	96	96	https://conductscience.org/library/drugs?q=MONDO_0004952
diffuse large B-cell lymphoma	Phase 3	ClinicalTrials.gov	93	93	https://conductscience.org/library/drugs?q=MONDO_0018905
neuroblastoma	Phase 3	ClinicalTrials.gov	56	56	https://conductscience.org/library/drugs?q=MONDO_0005072
non-small cell lung carcinoma	Phase 3	ClinicalTrials.gov	52	52	https://conductscience.org/library/drugs?q=MONDO_0005233
plasma cell myeloma	Phase 3	ClinicalTrials.gov	42	42	https://conductscience.org/library/drugs?q=MONDO_0009693
lymphoma	Phase 2/3	ClinicalTrials.gov	40	40	https://conductscience.org/library/drugs?q=MONDO_0005062

1 to 10 of 218Source Open Targets

See all 218 diseases

Trials1,468

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT02883049	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations	Phase 3	5,949	2024-03-12	etoposide	Its name	ClinicalTrials.gov
NCT00025259	Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease	Phase 3	1,734	2017-03-07	etoposide	Its name	ClinicalTrials.gov
NCT01371981	Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Phase 3	1,645	2020-07-07	etoposide	Its name	ClinicalTrials.gov
NCT01450761	Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone	Phase 3	1,351	2016-07-18	etoposide	Its name	ClinicalTrials.gov
NCT00134030	Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma	Phase 3	1,334	2023-06-07	etoposide	Its name	ClinicalTrials.gov
NCT03043872	Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)	Phase 3	987	2021-03-04	etoposide	Its name	ClinicalTrials.gov
NCT00003389	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma	Phase 3	854	2015-09-03	etoposide	Its name	ClinicalTrials.gov
NCT01492101	The BEACON Study (Breast Cancer Outcomes With NKTR-102)	Phase 3	852	2021-06-01	etoposide	Its name	ClinicalTrials.gov
NCT00632853	Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide	Phase 3	731	2023-06-12	etoposide	Its name	ClinicalTrials.gov
NCT00045162	S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer	Phase 3	671	2013-07-09	etoposide	Its name	ClinicalTrials.gov

1 to 10 of 1,468

See all 1,468 trials

Comparisons in its trials250

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
10 MG/KG IPILIMUMAB + PLATINUM/ETOPOSIDE vs PLACEBO + PLATINUM/ETOPOSIDE: serious adverse events	316 of 562	278 of 561	1,123	NCT01450761	Trial comparisons
Arm A (ABVD) vs Arm B (Stanford V): serious adverse events	355 of 414	401 of 422	836	NCT00003389	Trial comparisons
NKTR-102 vs Physician's Treatment of Choice: deaths from any cause	323 of 425	322 of 406	831	NCT01492101	Trial comparisons
NKTR-102 vs Physician's Treatment of Choice: serious adverse events	128 of 425	129 of 406	831	NCT01492101	Trial comparisons
Arm A (ABVD) vs Arm B (Stanford V): Incidence of Second Cancers	15 of 395	19 of 399	794	NCT00003389	Trial comparisons
Thalidomide vs No Thalidomide: serious adverse events	323 of 323	345 of 345	668	NCT00083551	Trial comparisons
Cisplatin + Irinotecan vs Cisplatin + Etoposide: Confirmed and Unconfirmed Complete and Partial Responses.	197 of 324	190 of 327	651	NCT00045162	Trial comparisons
Cisplatin + Irinotecan vs Cisplatin + Etoposide: serious adverse events	107 of 321	31 of 327	648	NCT00045162	Trial comparisons
Arm I (ABVE-PC) vs ARM II (Bv-AVEPC): deaths from any cause	4 of 289	2 of 298	587	NCT02166463	Trial comparisons
A Groups vs B Groups: Objective Response Rate	268 of 389	115 of 196	585	NCT04063163	Trial comparisons

1 to 10 of 250

See all 250 comparisons in its trials

Papers from its trials968

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41249450	RESULT	1	PubMed
40884462	RESULT	1	PubMed
40473974	RESULT	1	PubMed
40163214	RESULT	1	PubMed
40040254	RESULT	1	PubMed
39490738	RESULT	2	PubMed
39252865	RESULT	2	PubMed
38964333	RESULT	2	PubMed
38926066	RESULT	1	PubMed
38811992	RESULT	2	PubMed

1 to 10 of 968

See all 968 papers from its trials

Tests in its trials3

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Digit Span Test	2	1	ConductCognition
Verbal Learning	2	0	ConductCognition
Symbol Scan Task	1	0	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL44657

GET https://conductscience.org/api/drugs/v1/CHEMBL44657/diseases?page=2

API reference For AI assistants